CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Tarsus Pharmaceuticals, Inc. - TARS CFD

52.66
1.43%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon: 14:30 - 21:00

Tue: 14:30 - 18:00

Thu - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.30
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 51.92
Open 51.25
1-Year Change 168.04%
Day's Range 50.15 - 53.35
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 52.66 2.46 4.90% 50.20 53.38 50.05
Dec 19, 2024 51.92 -0.93 -1.76% 52.85 53.26 50.60
Dec 18, 2024 52.31 -0.87 -1.64% 53.18 56.45 51.69
Dec 17, 2024 53.20 1.99 3.89% 51.21 53.28 50.86
Dec 16, 2024 51.62 -0.72 -1.38% 52.34 53.52 51.07
Dec 13, 2024 52.45 3.79 7.79% 48.66 52.62 48.65
Dec 12, 2024 50.86 -0.67 -1.30% 51.53 52.45 49.63
Dec 11, 2024 52.09 1.54 3.05% 50.55 54.39 50.31
Dec 10, 2024 50.60 0.70 1.40% 49.90 51.54 49.90
Dec 9, 2024 50.61 -0.84 -1.63% 51.45 51.70 49.34
Dec 6, 2024 51.62 1.34 2.67% 50.28 51.89 49.74
Dec 5, 2024 50.27 -0.04 -0.08% 50.31 51.60 49.74
Dec 4, 2024 51.58 1.63 3.26% 49.95 51.94 49.55
Dec 3, 2024 50.34 0.39 0.78% 49.95 50.92 49.58
Dec 2, 2024 50.25 -2.15 -4.10% 52.40 52.51 49.71
Nov 29, 2024 52.40 1.60 3.15% 50.80 52.57 50.79
Nov 27, 2024 50.78 1.16 2.34% 49.62 51.33 49.56
Nov 26, 2024 49.62 1.67 3.48% 47.95 51.10 47.95
Nov 25, 2024 48.20 -0.02 -0.04% 48.22 48.95 47.61
Nov 22, 2024 48.13 1.76 3.80% 46.37 48.44 45.39

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Tarsus Pharmaceuticals, Inc. Company profile

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Tarsus Pharmaceuticals Inc revenues increased from $0K to $56.7M. Net income applicable to common stockholders totaled $1M vs. loss of $15.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to $0.05.

Industry: Pharmaceuticals (NEC)

15440 Laguna Canyon Road
IRVINE
CALIFORNIA 92618
US

People also watch

ETH/USD

3,326.39 Price
+0.300% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

US100

21,269.40 Price
+0.710% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

2.25 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01120

Gold

2,623.59 Price
+1.110% 1D Chg, %
Long position overnight fee -0.0151%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading